Document is current
Any future updates will be listed below
-
Authors
Thomas, Sylvia P.
Spinelli, Marcus M.
Rghei, Amira D.
Lopes, Jordyn A.
Zielinska, Nicole
McLeod, Benjamin M.
Pei, Yanlong
Zhang, Wei
Thebaud, Bernard
Karimi, Khalil
Wootton, Sarah K.
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (CHRP-2019-549701-20, CHRP-2019-549701-20)
Natural Sciences and Engineering Research Council of Canada (499834)
- License Information
-
More Information
Article History
Received: 22 November 2023
Accepted: 19 April 2024
First Online: 25 April 2024
Declarations
:
: This study was conducted according to the guidelines set forth by the Canadian Council on Animal Care (CCAC) and approved by the Animal Care Committee of the University of Guelph (Animal Use Protocol number 4664).
: Not applicable.
: S.K.W. is a scientific founder of Avamab Pharma Inc., a pre-clinical, pre-revenue stage company dedicated to research and development of AAV gene therapies for the treatment and prevention of infectious diseases. S.K.W. and B.T. are co-founders of Inspire Biotherapeutics, a pre-clinical, pre-revenue stage gene therapy company developing AAV-based therapies for monogenic lung diseases. S.K.W. and B.T. are inventors on issued patents in Canada and US for the AAV6.2FF capsid, which are owned by the University of Guelph, and licensed to Avamab Pharma Inc., Inspire Biotherapeutics, and Cellastra Inc. The other authors have no competing interests to declare.
